Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

HRS-2398

Alternative Names: hrs-2398, hrs 2398, hrs2398
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

For Advanced Malignant Tumor (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05144061)

Mechanisms of Action: ATR Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Shanghai Hengrui Pharmaceutical
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for HRS-2398

Countries in Clinic: China

Active Clinical Trial Count: 3

Highest Development Phases

Phase 2: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
HRS2398-201-PD-L1

P2

Recruiting

Oncology Solid Tumor Unspecified

2025-12-01

HRS2398-I-101

P1

Completed

Oncology Solid Tumor Unspecified

2024-02-21

CTR20212596

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

None

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions